Vaccines

23 June 2015

Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine

22 June 2015

Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease

18 June 2015

Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101

18 June 2015

BiondVax Announces FDA Acceptance of IND Application for its Investigational Universal Flu Vaccine

16 June 2015

Genticel Receives FDA Clearance of IND Application for US Phase 1 Clinical Trial of GTL001 (ProCervix), Company’s First-in-Class HPV Therapeutic Vaccine Candidate

15 June 2015

Heat Biologics Announces Development of ComPACT, a Next Generation Combination Immunotherapy Platform

10 June 2015

Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout

10 June 2015

Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine

8 June 2015

Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy

8 June 2015

DBV Technologies Presents Clinical and Scientific Data at the EAACI Congress

5 June 2015

Independent Data Monitoring Committee Recommends Continuation of Pivotal ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma

4 June 2015

ALK Announces Top-Line Results From Its Partner MSD’s North American Phase III Trial of House Dust Mite SLIT-Tablet

3 June 2015

VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, into Phase 2 Study

3 June 2015

VBI Vaccines Presents Data at the World Vaccine Congress Asia That Supports the Potential Use of Its eVLP Platform in the Development of a Novel Hepatitis C Vaccine Candidate

2 June 2015

Ichor Partner Scancell Announces Update on SCIB1 Phase 1/2 Clinical Trial in Stage III and IV Melanoma Patients

2 June 2015

ORYX Presents Positive Phase I/IIa Data with Therapeutic Vaccine MicOryx to Treat MSI-H Colorectal Cancers at ASCO 2015

2 June 2015

Targovax Releases TGO1 RAS-Mutation-Specific Immunotherapy Data at ASCO

1 June 2015

Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma

1 June 2015

Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics’ AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)

1 June 2015

Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

1 June 2015

Genticel announces positive preclinical proof of concept results of GTL002, its new multivalent HPV therapeutic vaccine candidate based on company’s versatile vaxiclase platform

31 May 2015

Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met

28 May 2015

PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy

27 May 2015

Inovio Pharmaceuticals Partners with GeneOne Life Science for MERS Immunotherapy Clinical Development

27 May 2015

GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients

21 May 2015

Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients

21 May 2015

Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003

19 May 2015

CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study

13 May 2015

Oxford University, GSK, and Emergent BioSolutions Announce Initiation of a Prime Boost Study of Ebola Vaccine Candidates

13 May 2015

Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE® Smallpox Vaccine

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TSLP Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review